5544 results about "Antigen Binding Fragment" patented technology

The disclosure relates to methods, compositions, and combinations for the treatment of endometrial cancer. Specifically, the disclosure relates to methods of treating endometrial cancer in a subject in need thereof, comprising administering to the subject one or more chemotherapy agents, an anti-PD-L1 antibody or an antigen-binding fragment thereof, and optionally a PARP inhibitor. The disclosure also relates to combinations for use in the treatment of endometrial cancer comprising one or more chemotherapy agents, an anti-PD-L1 antibody or an antigen-binding fragment thereof, and optionally a PARP inhibitor.

The invention relates to a monoclonal antibody for detecting folic acid and a binding protein complex thereof or an antigen binding fragment thereof, and a preparation method and application thereof, the monoclonal antibody or the antigen binding fragment thereof comprises: (1) a heavy chain variable region having an amino acid sequence as shown in SEQ ID NO.1, SEQ ID NO.2 and SEQ ID NO.3, HCDR1, HCDR2 and HCDR3, and (2) a heavy chain variable region having an amino acid sequence as shown in SEQ ID NO.3; the light chain variable region is provided with an LCDR1, an LCDR2 and an LCDR3, and the amino acid sequences of the LCDR1, the LCDR2 and the LCDR3 are respectively shown as SEQ ID NO.4, SEQ ID NO.5 and SEQ ID NO.6. The monoclonal antibody or the antigen binding fragment thereof can bind folic acid and a protein compound thereof with high specificity and high affinity, so that the detection accuracy and sensitivity of folic acid are improved, the limitation that a traditional competition method detection reagent is low in sensitivity and poor in clinical correlation is broken through, and sandwich method immunodetection of folic acid is realized.

The invention discloses a monoclonal antibody for distinguishing a hog cholera lapinized virus vaccine strain and a hog cholera lapinized virus epidemic strain and application of the monoclonal antibody, and belongs to the field of immune globulin. The E2 protein monoclonal antibody or the antigen binding fragment thereof comprises a heavy chain variable region (SEQ ID No.1) and a light chain variable region (SEQ ID No.3). The invention also discloses an ELISA method for identifying and distinguishing hog cholera lapinized virus vaccine strains and epidemic strains by using the E2 protein monoclonal antibody. The monoclonal antibody disclosed by the invention has a specific reaction with the swine fever virus epidemic strain and does not react with the swine fever lapinized virus vaccine strain, and the swine fever lapinized virus vaccine strain and the epidemic strain can be accurately identified and distinguished by utilizing an ELISA competition method established by the monoclonal antibody. The monoclonal antibody provided by the invention can be used in the fields of CSFV immunization, serological diagnosis of wild viruses, immune effect evaluation, related experiments and the like, and provides antibody resources for effective detection and purification of CSFV.

Provided are novel antibodies targeting CD3 and one or more other targets, or antigen-binding fragments thereof, isolated polynucleotides encoding the same, pharmaceutical composition comprising the same and the uses thereof.

The invention discloses preparation of a targeting LYPD3 antibody and application of the targeting LYPD3 antibody in tumor immunotherapy. The antibody or antigen binding fragment thereof comprises a heavy chain variable region having CDR-H1, CDR-H2 and CDR-H3 and a light chain variable region having CDR-L1, CDR-L2 and CDR-L3 wherein CDR-H1, CDR-H2 and CDR-H3 comprise the amino acid sequences of SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5, respectively, and CDR-L1, CDR-L2 and CDR-L3 comprise the amino acid sequences of SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO: 8, respectively.

The invention discloses an anti-pestivirus broad-spectrum neutralizing monoclonal antibody and application thereof, and belongs to the field of immune globulin. The anti-pestivirus monoclonal antibody or the antigen binding fragment thereof comprises a heavy chain variable region (SEQ ID No.1) and a light chain variable region (SEQ ID No.3). The monoclonal antibody provided by the invention can identify hog cholera virus and all known plague virus members (BVDV1, BVDV2, BDV, HoBiPeV, AydinPeV and OVPV) capable of infecting cattle and sheep at present, has good neutralizing ability, and can be prepared into a diagnostic product for plague virus antigen-antibody detection. The monoclonal antibody and a diagnostic product developed based on the monoclonal antibody can be used for serological diagnosis and immune effect evaluation of pestivirus, pestivirus pathogen detection of experimental serum products and the like, and have wide application prospects in the fields of clinical diagnosis and the like.

The invention provides a monoclonal antibody of a p-Tau217 protein and an application of the monoclonal antibody. In particular, the present invention provides an antibody or an antigen binding fragment thereof targeting a p-Tau217 protein. The antibody provided by the invention can specifically recognize and bind the p-Tau217 protein, does not recognize p-Tau181 and non-phosphorylated Tau protein, and can be used for preparing a detection preparation or a kit for diagnosing diseases related to the p-Tau217 protein, such as Alzheimer's disease.

The invention discloses a specific antibody aiming at a CysR structural domain of PLA2R and application of the specific antibody, and belongs to the technical field of biological engineering. The invention provides a CysR structural domain antibody of PLA2R or an antigen binding fragment of the CysR structural domain antibody. The CysR structural domain antibody or the antigen binding fragment thereof provided by the invention can specifically recognize the corresponding PLA2R structural domain and has relatively high affinity. Besides, the invention provides a method for establishing a standard curve by using a CysR structural domain antibody of PLA2R as a standard substance, so that convenience is provided for clinical detection of concentrations of IgG with different anti-PLA2R epitopes.

Provided are anti-PD-1 antibodies and trispecific antibodies specifically binding to PD-1, CTLA-4 and VEGF, or antigen-binding fragments thereof, polynucleotides encoding the antibodies or antigen-binding fragments thereof, and methods of making and using the foregoing.

The present invention provides antibodies, or antigen binding fragments thereof, capable of binding to leukocyte immunoglobulin-like receptor subfamily B member 2 (LILRB2). The invention also provides application of the antibody or the antigen binding fragment thereof in preparation of drugs for treating diseases related to high expression of LILRB2. The antibody or the antigen binding fragment thereof provided by the invention can bind to human LILRB2 with high affinity, block the binding of the LILRB2 and the ligand HLA-G thereof, and enhance the T cell function.

The invention relates to a monoclonal antibody for detecting human metapneumovirus, a detection reagent and application of the monoclonal antibody and the detection reagent. The monoclonal antibody or the antigen binding fragment thereof can be specifically bound with the human metapneumovirus N protein with higher affinity, has broad-spectrum effectiveness on various genotypes, and has no cross reactivity with other respiratory viruses, so that the monoclonal antibody or the antigen binding fragment thereof has huge potential application value in clinical detection of human metapneumovirus infection.

The present invention relates to the field of biomedicine, and specifically provides an antibody binding to IL-11 or antigen-binding fragment thereof, comprising three heavy-chain complementarity-determining regions respectively represented by HCDR1, HCDR2, and HCDR3, and three light-chain complementarity-determining regions respectively represented by LCDR1, LCDR2, and LCDR3, the antibody or antigen-binding fragment thereof being selected from A-I, A-II, A-III, or A-IV. The provided antibody or antigen-binding fragment thereof has high binding capacity to the IL-11 antigen and can block the IL-11 antigen from binding to receptors thereof, thus effectively inhibiting the pro-fibrotic effect of IL-11 and inhibiting or preventing the generation or proliferation of fibroblasts, and can be effectively used for treating or preventing human fibrotic diseases, inflammation, cancers, or autoimmune diseases.

Methods for treating or preventing asthma (e.g., allergic asthma, asthma associated with allergic bronchopulmonary aspergillosis (ABPA), moderate-to-severe asthma, persistent asthma or the like) and associated conditions (e.g., ABPA, ABPA comorbid with asthma, ABPA comorbid with cystic fibrosis (CF), ABPA comorbid with asthma and CF) in a subject are provided. Methods comprising administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody or antigen-binding fragment thereof, are provided.

The invention discloses a monoclonal antibody of Japanese encephalitis virus and Zika virus and application of the monoclonal antibody, and relates to the technical field of immunology and molecular virology. The monoclonal antibody or the antigen binding fragment thereof comprises a VH CDR1, a VH CDR2 and a VH CDR3 of which the amino acid sequences are as shown in SEQ ID NO: 1-3, and a VL CDR1, a VL CDR2 and a VL CDR3 of which the amino acid sequences are as shown in SEQ ID NO: 4-6. A large number of experimental studies show that the monoclonal antibody can specifically recognize and target extracellular regions of E proteins of the Japanese encephalitis virus and the Zika virus, can block combination of the E proteins and cell surface receptors, and shows efficient virus neutralizing capacity. Therefore, the antibody provided by the invention is particularly suitable for being used for diagnosing, preventing and / or treating diseases related to Japanese encephalitis virus and Zika virus infection.

The present invention relates to the field of biotechnology and medicine, in particular to a monoclonal antibody or antigen-binding fragment thereof that specifically binds to TNF-like ligand 1A (TL1A). The invention further relates to nucleic acids encoding said antibody, expression vectors, host cells and methods for producing same, methods for producing the antibodies according to the invention, pharmaceutical compositions comprising the antibody or antigen-binding fragment thereof according to the invention, as well as to pharmaceutical compositions comprising the antibody or antigen-binding fragment thereof according to the invention and other therapeutically active compounds; to methods for treating TL1A-mediated diseases or disorders, to use of the antibody or antigen-binding fragment thereof or pharmaceutical composition thereof for treating TL1A-mediated diseases or disorders, and to use of the antibody or antigen-binding fragment thereof according to the invention and other therapeutically active compounds for treating TL1A-mediated diseases or disorders.

The present invention provides a combination of (i) an immune checkpoint modulator and (ii) a T-cell redirecting multifunctional antibody, or an antigen binding fragment thereof, for use in therapeutic treatment of a cancer disease. The T-cell redirecting multifunctional antibody comprises (a) a specificity against a T cell surface antigen; (b) a specificity against a cancer- and / or tumor-associated antigen; and (c) a binding site for human FcγRI, FcγRIIa and / or FcγRIII, wherein the antibody, or the antigen binding fragment thereof, binds with a higher affinity to human FcγRI, FcγRIIa and / or FcγRIII than to human FcγRIIb.

The invention provides a specific T cell receptor targeting KRAS G12V mutant epitope peptide (such as an amino acid sequence as shown in SEQ ID NO: 2) and anti-tumor application of the specific T cell receptor. The specific T cell receptor is composed of two peptide chains alpha and beta and can be specifically combined with a VVGAVGVGK-HLA-A * 11: 01 compound. The invention also provides an antigen binding fragment of the specific T cell receptor, a nucleic acid sequence for coding the T cell receptor, a vector containing the nucleic acid sequence, an engineered cell for expressing the T cell receptor, a composition containing the T cell receptor and application thereof. In addition, the invention also provides a method for screening the KRAS G12V specific T cell receptor. The specific T cell receptor and the antigen binding fragment thereof provided by the invention can be used as an immune effect activator to stimulate the immune response of a body, so that the effect of resisting diseases such as tumors and the like is achieved.

Provided is an antibody or antigen-binding fragment that binds to NKG2A, and uses thereof. The antibody or antigen-binding fragment binding to NKG2A can improve the immune response and the lysis of HLA-E expressed tumor cells.

A hydrogel particle, comprising a matrix comprising a polymerized monomer, said matrix comprising a plurality of micropores and a plurality of macropores, and one or more immunostimulatory biomolecules selected from the group consisting of an anti-CD3 antibody or antigen-binding fragment thereof, an anti-CD28 antibody or antigen-binding fragment thereof, and combinations thereof.

Provided is an antibody or an antigen-binding fragment thereof that is useful for the examination of cancer, in particular for early cancer. An antibody or an antigen-binding fragment thereof, comprising a heavy chain CDR1 comprising the amino acid sequence represented by SEQ ID NO: 1, a heavy chain CDR2 comprising the amino acid sequence represented by SEQ ID NO: 2, a heavy chain CDR3 comprising the amino acid sequence represented by SEQ ID NO: 3, a light chain CDR1 comprising the amino acid sequence represented by SEQ ID NO: 4, a light chain CDR2 comprising the amino acid sequence represented by SAS, and a light chain CDR3 comprising the amino acid sequence represented by SEQ ID NO: 6.

The invention provides a group of specific antibodies for detecting botulinum toxin A and application thereof, and belongs to the technical field of botulinum toxin detection. The invention provides a group of specific antibodies for detecting botulinum toxin A or antigen binding fragments thereof. The specific antibodies or the antigen binding fragments thereof comprise a rabbit monoclonal antibody 1F11 or an antigen binding fragment thereof and a rabbit monoclonal antibody 2A10 or an antigen binding fragment thereof. The time-resolved immunodetection kit prepared by the invention has good detection sensitivity, specificity, repeatability and sample matrix tolerance, the detection range is 0.02 ng / mL-10 ng / mL, the detection limit is 0.02 ng / mL, cross reaction with other serotype botulinum toxins (B, E and F) does not exist, and the time-resolved immunodetection kit is not influenced by sample matrixes such as ham sausages and thick broad-bean sauce. The detection system established by the invention has a good application prospect in detection of botulinum toxin type A.

The present disclosure provides an antibody or antigen-binding fragment thereof that specifically binds to human cMET. The disclosure also provides polynucleotides encoding the antibodies or antigen binding fragments thereof, vectors comprising the polynucleotides, host cells comprising the vectors, methods of generating the antibodies, and compositions comprising the antibodies.

The invention provides an anti-S100A8 / A9 antibody and application of the anti-S100A8 / A9 antibody. The antibody or the antigen binding fragment and the mutant thereof provided by the invention can block the biological function of S100A8 / A9. The antibody or the antigen binding fragment provided by the invention is expected to be developed into a clinical drug, so that the cardiac infarction area of an AMI patient is reduced, the occurrence of heart failure is reduced, the AMI patient is benefited for the whole life, and the antibody or the antigen binding fragment has important clinical significance and development value.

To address the need in the art, the inventors have comprehensively characterized Aspects of the disclosure relate to novel antibody and antigen binding fragments. Further aspects relate to polypeptides comprising the antigen binding fragment(s) of the disclosure, and compositions comprising the polypeptides, antibodies, and / or antigen binding fragments of the disclosure. Also described are nucleic acids encoding an antibody or antigen binding fragment of the disclosure.

The invention relates to the technical field of antibodies, and provides an anti-CD45 antibody for detecting a white blood cell common antigen based on flow cytometry and application of the anti-CD45 antibody, the antibody comprises at least one of the following CDRs: a heavy chain variable region CDR: an amino acid sequence of SEQ ID NO: 1-3 or a conservatively modified form thereof; and a light chain variable region CDR: SEQ ID NO: 4-6 or an amino acid sequence in a conservative modification form thereof. The antibody or the antigen binding fragment thereof can efficiently and specifically recognize CD45, and can effectively detect the CD45.

The present invention relates to the field of biological medicine, and particularly provides an IL-11 binding antibody or an antigen binding fragment thereof, the antibody comprises three heavy chain complementarity determining regions represented by HCDR1, HCDR2 and HCDR3 respectively and three light chain complementarity determining regions represented by LCDR1, LCDR2 and LCDR3 respectively, and the antibody or the antigen binding fragment thereof is selected from A-I, A-II, A-III or A-IV. The antibody or the antigen binding fragment thereof provided by the invention has relatively high binding capacity with the IL-11 antigen, and can block the binding of the IL-11 antigen and a receptor thereof, so that the fibrosis promoting effect of the IL-11 is effectively inhibited, the generation or proliferation of fibrocytes is inhibited or prevented, and the anti-fibrosis effect of the IL-11 is improved. The compound can be effectively used for treating or preventing human fibrosis diseases, inflammations, cancers or autoimmune diseases.

Provided are an anti-CD3 antibody or an antigen-binding fragment thereof, and a use thereof. The anti-CD3 antibody comprises: heavy chain variable region CDRs and light chain variable region CDRs, the heavy chain variable region CDRs having amino acid sequences as shown in any one of SEQ ID NOs: 1-3, 7-8 and 74-86 or a conservatively modified form thereof, and / or the light chain variable region CDRs having amino acid sequences as shown in any one of SEQ ID NOs: 4-6, 9 and 87-92 or a conservatively modified form thereof. The provided anti-CD3 antibody or antigen-binding fragment thereof can bind to human CD3 protein and reduce the production of pro-inflammatory cytokines, and a bispecific antibody constructed using same has high PBMC tumor-killing activity and weak promotion of the secretion of pro-inflammatory cytokines. A pharmaceutical composition prepared using the anti-CD3 antibody or the antigen-binding fragment thereof or a multi-specific antibody thereof has better safety, and has value for clinical applications and drug development.

This disclosure provides an antibody or antigen-binding fragment or derivative thereof that specifically binds to CD38. Also provided are polynucleotides encoding the antibody or antigen-binding fragment or derivative thereof and vectors and host cell comprising said poly nucleotides. This disclosure further provides methods for producing and / or using an antibody or antigen-binding fragment or derivative thereof that specifically binds to CD38.

Provided are methods of treating a cellular proliferative disorder (e.g., cancer) comprising administering: (a) an anti-human PD-1 antibody or antigen binding fragment thereof; and (b) an Immunoconjugate of Formula (I) : wherein: Ab is an antibody that binds to Trop-2; and n is an integer from 1 to 10. Also disclosed are therapeutic combinations and kits containing such agents for the treatment of cancers.

The invention belongs to the field of biological medicine, and relates to an anti-SEZ6 nano antibody or antigen binding fragment and application. The anti-SEZ6 nano antibody or the antigen binding fragment comprises three complementary determining regions, namely, CDR1, CDR2 and CDR3; the sequences of all the regions are respectively shown as SEQ ID NO: 1 to SEQ ID NO: 18. Compared with a conventional antibody, the anti-SEZ6 nano antibody is efficient in expression, simple in purification, small in molecular weight, high in affinity, relatively good in specificity, high in solubility and strong in tolerance, and can be widely applied to the fields of scientific research, diagnosis and treatment.